Hanmi Pharm is currently trading at 397,500 KRW, down 1.85% from the previous day as of 2:31 PM on the 28th. The trading volume is 165,495 shares, which is 23.39% of the previous day's volume. Hanmi Pharm is known as a pharmaceutical company specializing in the production of prescription drugs.
On January 25, Kiwoom Securities researcher Heo Hyemin stated, "The FDA PDUFA date for Oraksol is on 2/28, and Rolontis is also expected to be approved within the year. This year's performance is expected to be strong due to the base effect, milestone payments, and royalty inflows, and the interim results of the triple agonist phase 2b trial are anticipated, providing R&D momentum. It is still unknown whether the company will secure a COVID vaccine CMO contract, but if it does, further upward revisions to earnings are possible." He set Hanmi Pharm's target price at 460,000 KRW.
Over the past five days, individual investors have net sold 177,983 shares of Hanmi Pharm, while foreigners and institutions have net bought 105,459 shares and 69,353 shares, respectively.
※Source: AI Investment Assistant AI Rassiro
※ This article was generated in real-time by an automated article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
